Patent Grant
9040701
This application is filed under the provisions of 35 U.S.C. §371 and claims the priority of International Patent Application No. PCT/ES2010/000349 filed on 29 Jul. 2010 entitled “APAF-1 Inhibitor Compounds” in the name of Ángel MESSEGUER PEYPOCH, et al., which claims priority of Spanish Patent Application No. p200901757 filed on 30 Jul. 2009, both of which are hereby incorporated by reference herein in their entirety.
The present invention relates to compounds for the prophylaxis and/or treatment of disorders caused by apoptotic cell death or for the prevention of degenerative processes caused by apoptotic cell death.
Apoptosis or programmed cell death is a complex physiological phenomenon involved in the maintenance of cell homeostasis. Apoptosis is regulated by various cell control mechanisms due to its key role in health maintenance. Many pathologies are based on apoptosis dysfunction. Therefore, an excess of apoptotic cell death can affect tissue functionality (e.g. cardiomyocyte death in the cases of myocardial infarction), whereas an excessively inhibited apoptosis entails uncontrolled cell survival (e.g. neoplastic processes). The cell components regulating apoptosis are in constant dynamic equilibrium in a healthy cell. There are at least two well characterized activation pathways for the apoptotic caspase cascade. One of them, the extrinsic pathway, is activated by extracellular signaling and requires the participation of specific membrane receptors. The intrinsic pathway corresponds to cellular stress, toxic agents, radiation, oxidizing agents, Ca2+ overloading, DNA injury; it is activated in response to oncogenes and involves mitochondrial destabilization. In some pathophysiological conditions (for example, anoxia in cells of organs to be transplanted, treatment with toxic substances), apoptosis increases and an excessive number of cells die, crippling the functionality of the affected tissue and compromising its survival in some cases.
The molecular apoptosis induction mechanisms entail the activation of proteins with protease activity called caspases which are also known as effectors of apoptosis. The formation of a molecular complex called apoptosome is necessary to enable activating the caspases. Apoptosome is formed by cytochrome c, pro-caspase-9 and the apoptotic peptidase activating factor 1 (Apaf-1). It has been demonstrated that Apaf-1 inhibition inhibits the formation of the apoptosome complex and that it causes an apoptosis inhibition (measured through caspase 3 activation). In cell assays in which apoptosis is induced by means of hypoxia (reducing the air oxygen concentration) or by means of chemical compounds, an increase of cell survival has been observed when the latter have been previously treated with apoptosis inhibitors.
Likewise, during the process of removing and transplanting an organ, its cells are subjected to a hypoxia condition which can lead to cell death compromising the organ viability and functionality. Therefore, for example, only 70% of all the corneas donated for transplant are suitable to be implanted. This is due to the fact that apoptotic cell death occurs during cornea storage. A similar situation occurs during kidney and heart transplants. There are solutions on the market for transporting organs exclusively providing buffered and sterile environments but they do not contain any active molecule which prevents apoptotic cell death.
The study of the mechanisms involved in apoptosis has allowed identifying different potential pharmacological targets. Therefore, inhibitors acting at different levels of the apoptotic cascade such as transcription factors, kinases, regulators of mitochondrial membrane permeabilization and inhibitors of the caspase family have been designed.
Since the formation of apoptosome is a key step in the apoptotic cascade and the subsequent activation of the caspases, the inhibition of Apaf-1 activation can have a greater impact on apoptosis inhibition than other pharmacological targets studied. There are indications in the scientific literature about the therapeutic implications of Apaf-1 inhibition. Therefore the transduction of an Apaf-1 dominant negative by means of an adenovirus in an animal model of Parkinson's was more effective than the transduction of a caspase-1 dominant negative by means of an adenovirus.
Document WO2007060524 describes derivative compounds of [1,4]diazepan-2,5-dione of the following formula as apoptosis inhibitors.
Document WO2008009758 describes the compounds of the following formula as UBC13-UEV interaction inhibitors which can be used in the preparation of pharmaceutical compositions for anti-tumor therapy or for the treatment and/or prophylaxis of diseases associated with metabolic pathways involving the enzyme UBC13, metabolic pathways involving transcription factor NF-kB, or pathways involving PCNA or RAD6. Although they can be considered as structurally similar to those of the present invention, they have a different use.
R—(CR1R2)q—CO—N(R3)—C(R4R5)—CO—NH2
It is therefore desirable to provide new Apaf-1 inhibitor compounds.
The present invention provides new derivative compounds of 2,5-piperazinedione of formula (I) having APAF-1 inhibiting activity.
Therefore, a first aspect of the invention relates to compounds of formula (I)
and pharmaceutically acceptable salts thereof, wherein:
R1 and R2 are independently selected from —H, —C1-5 alkyl, —C2-5 alkenyl, —(CH2)0-3-cycloalkyl, —(CH2)1-3-heterocycle, —(CH2)0-3-aryl, —(CH2)0-3-heteroaryl, —(CH2)1-2—CH(aryl)2, —(CH2)1-2—CH(aryl)(heteroaryl) and —(CH2)1-2—CH(heteroaryl)2,
R3 is selected from —H, —C1-5 alkyl, —C2-5 alkenyl, —(CH2)0-3-cycloalkyl, —(CH2)1-3-heterocycle, —(CH2)1-3-aryl, —(CH2)1-3-heteroaryl, —(CH2)1-3—CONR5R6, —(CH2)1-2—CH(aryl)2, —(CH2)1-2—CH(aryl)(heteroaryl) and —(CH2)1-2—CH(heteroaryl)2,
R4 is selected from —H, —C1-5 alkyl, —(CHR7)1-3—CO—NR5R6, —(CHR7)1-3—CO—OR5, —(CH2)1-3—NR5R6, —(CH2)1-3—CO[NCHR7CO]mNH2 and —(CH2)1-3—CO[NCHR7CO]mOR5,
n is an integer selected from 1 and 2;
m is an integer selected from 1, 2 and 3;
R5 and R6 are independently selected from —H, —C1-5 alkyl and —(CH2)0-3-aryl,
R7 is selected from —H, —C1-5 alkyl, —(CH2)1-3-aryl and —(CH2)1-3-heteroaryl, such that when m is greater than 1 the R7 substituents can be equal to or different from one another,
wherein the C1-5 alkyl, C2-5 alkenyl, cycloalkyl and heterocycle groups can be optionally substituted with one or several substituents selected independently from halogen, OR5, OCF3, SH, SR5, NR5R6, NHCOR5; COOH, COORS, OCOR5, aryl and heteroaryl,
wherein the aryl and heteroaryl groups can be optionally substituted with one or several substituents selected independently from halogen, CF3, OR5, OCF3, SH, SR5, NH2, NHCOR5; NO2, CN, COR5, COOR5, OCOR5, CONR5R6, —(CH2)0-3NR5R6, SO2NH2, NHSO2CH3, C1-5 alkyl, aryl and heteroaryl,
wherein the heterocycle and heteroaryl groups can be optionally substituted on a secondary nitrogen atom with
C1-5 alkyl, cycloalkyl or —(CH2)0-3-aryl,
on the condition that when R2 is 2-(4-fluorophenyl)ethyl, R4 is —CH2—CO—NH2 and n is 1, then:
In a particular embodiment of the invention, R1 is —C1-5 alkyl or —(CH2)0-3-aryl.
In another particular embodiment of the invention, R2 is —C1-5 alkyl, —(CH2)0-3-aryl, —(CH2)0-3-heteroaryl or —(CH2)1-2—CH(aryl)2.
In another particular embodiment of the invention, R3 is —H, —C1-5 alkyl, —(CH2)1-3-heterocycle, —(CH2)1-3-aryl or —(CH2)1-3-heteroaryl.
In another particular embodiment of the invention, R4 is —H, —(CHR7)1-3—CO—NR5R6, —(CHR7)1-3—CO—OR5 or —(CH2)1-3—CO[NCHR7CO]mNH2.
In another particular embodiment of the invention, n is 1.
In another particular embodiment of the invention, m is 1.
In another particular embodiment of the invention, R5 is —H or —C1-5 alkyl.
In another particular embodiment of the invention, R6 is —H.
In another particular embodiment of the invention, R7 is —H, —C1-5 alkyl, —(CH2)1-3-aryl or —(CH2)1-3-heteroaryl.
A second aspect of the present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof for use as an active pharmaceutical ingredient, particularly for use in the prophylaxis and/or treatment of a pathological and/or physiological condition associated with an increase of apoptosis, wherein the pathological and/or physiological condition associated with an increase of apoptosis is selected from organ or cell preservation, particularly transplant or conservation; cytotoxicity prevention, particularly cytotoxicity mediated by chemicals, by physical agents such as radiation, acoustic trauma, burns, or by biological agents such as hepatitis virus infection; pathologies due to hypoxia conditions, such as heart attack or cerebral infarction; eye pathologies, such as injuries caused by eye surgery, age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa or glaucoma; neurodegenerative diseases, such as Alzheimer's, Huntington's, Parkinson's or amyotrophic multiple sclerosis; diabetes, particularly preservation of islets of Langerhans or diabetes-associated cytotoxicity such as, for example, nephrotoxicity; osteoarthritis; arthritis; inflammation or immunodeficiencies, such as AIDS-associated CD4+ T lymphocyte depletion.
Another aspect of the present invention relates to the use of a compound of formula (I) or of a pharmaceutically acceptable salt thereof for the manufacture of a medicament intended for the prophylaxis and/or treatment of a pathological and/or physiological condition associated with an increase of apoptosis, particularly one of the aforementioned conditions.
Another aspect of the present invention relates to a method of prophylaxis and/or treatment of an individual or organ suffering or susceptible to suffering a pathological and/or physiological condition associated with an increase of apoptosis, particularly one of the aforementioned conditions, comprising the administration of a therapeutically effective amount of a compound of formula (I) or of a pharmaceutically acceptable salt thereof to said individual or organ together with sufficient amounts of pharmaceutically acceptable excipients.
The compounds of formula (I) and the pharmaceutically acceptable salts thereof, particularly the compounds of formula (I) described as examples or as intermediates are preferred.
The compounds of the present invention can be used alone or in combination with one or more compounds which are useful for the prophylaxis and/or treatment of a pathological and/or physiological condition associated with an increase of apoptosis, such as organ or cell preservation, particularly transplant or conservation; cytotoxicity prevention, particularly cytotoxicity mediated by chemicals, by physical agents such as radiation, acoustic trauma, burns, or by biological agents such as hepatitis virus infection; pathologies due to hypoxia conditions, such as heart attack or cerebral infarction; eye pathologies, such as injuries caused by eye surgery, age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa or glaucoma; neurodegenerative diseases, such as Alzheimer's, Huntington's, Parkinson's or amyotrophic multiple sclerosis; diabetes, particularly preservation of islets of Langerhans or diabetes-associated cytotoxicity such as, for example, nephrotoxicity; osteoarthritis; arthritis; inflammation or immunodeficiencies, such as AIDS-associated CD4+ T lymphocyte depletion.
The term “C1-5 alkyl”, alone or in combination, means a linear- or branched-chain alkyl group having 1 to 5 carbon atoms.
The term “C2-5 alkenyl”, alone or in combination, means a linear- or branched-chain group having 2 to 5 carbon atoms and having one or more unsaturated bonds.
The term “cycloalkyl”, alone or in combination, refers to a stable monocyclic radical of 3 to 7 members, which is saturated or partially saturated, and which only consists of carbon and hydrogen atoms. Examples of cycloalkyl are the following: cyclopropyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, cycloheptyl.
The term “heterocycle”, alone or in combination, means a saturated or partially unsaturated heterocycle of 5 to 10 links, containing one or several heteroatoms chosen from nitrogen, oxygen and sulfur. For the purposes of this invention, the heterocycle can be a monocyclic or bicyclic ring system which can include condensed ring systems. Examples of heterocycle groups are tetrahydrofuranyl (THF), dihydrofuranyl, dioxanyl, morpholyl, piperazinyl, piperidinyl, 1,3-dioxolanyl, imidazolidinyl, imidazolinyl, pyrrolidyl, pyrrolidinyl, tetrahydropyranyl, dihydropyranyl, and the like.
The term “aryl”, alone or in combination, refers to a mono- or polycyclic aromatic ring system containing carbon ring atoms. The preferred aryls are monocyclic or bicyclic aromatic ring systems of 5-10 members, such as phenyl or naphthyl having optionally one or several substituents, preferably from one to three selected independently from halogen, CF3, OH, ORS, OCF3, SH, SRS, NH2, NHCOR5; NO2, CN, COR5, COOR5, OCOR5, CONR5R6, —(CH2)0-3NR5R6, SO2NH2, NHSO2CH3, C1-5 alkyl, aryl and heteroaryl.
The term “heteroaryl”, alone or in combination, refers to an aromatic or partially aromatic heterocycle containing at least one ring heteroatom selected from O, S and N. Heteroaryls thus includes heteroaryls condensed to other classes of rings, such as aryls, cycloalkyls and heterocycles which are not aromatic. Examples of heteroaryl groups include: pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, furyl, thienyl, pyrimidyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, dihydrobenzofuranyl, indolinyl, pyridazinyl, indazolyl, isoindolyl, dihydrobenzothienyl, indolizinyl, quinazolinyl, naphthyridinyl, isobenzylfuranyl, benzimidazolyl, benzofuranyl, benzothienyl, quinolyl, indolyl, isoquinolyl, dibenzofuranyl, benzothiophenyl, tetrahydrobenzothiophenyl and the like.
The expression “optionally substituted with one or several substituents” means that a group can be unsubstituted or substituted with one or several substituents, preferably with 1, 2, 3 or 4 substituents, provided that said group has 1, 2, 3 or 4 positions susceptible to be substituted.
The term “pharmaceutically acceptable salts” means those salts which conserve the efficiency and the biological properties of the free bases or free acids and which do not cause discomfort in a biological sense or in any other sense.
According to the invention, the compounds of formula (I) and their pharmaceutically acceptable salts are useful for the prophylaxis and/or treatment of a pathological and/or physiological condition associated with an increase of apoptosis by means of their APAF-1 inhibiting activity.
Unless defined otherwise, all the technical and scientific terms used herein have the same meaning as those commonly understood by a person skilled in the field of the invention. Methods and materials which are similar or equivalent to those described herein can be used in practicing the present invention. Throughout the description and claims the word “comprises” and its variants do not aim to exclude other technical features, additives, components, steps or stereoisomers of the compounds involved. For the persons skilled in the art, other objects, advantages and features of the invention will be inferred partially from the description and partially from practicing the invention.
The compounds of formula (I) can be prepared following different methods known by any person skilled in the field of organic synthesis, particularly through the general processes shown in the following schemes. The starting materials for the preparative methods are commercially available or they can be prepared by means of methods of the literature. Unless indicated otherwise, the meaning of groups R1, R2, R3, R4, R5, R6 and R7 are those described in the general formula (I).
The compounds of formula (I) can be obtained from the methods and schemes described below:
According to Method A, once the fluorenemethyloxycarbonyl group is deprotected, the amine II bound to the solid support is acylated with an acylating agent III, wherein X represents a leaving group, for example a halogen and Y represents OH or halogen. When Y represents a halogen, for example chloroacetyl chloride, the reaction can be performed in the presence of a base such as triethylamine. When Y represents —OH, for example bromoacetic acid, the reaction can be carried out in the presence of a suitable coupling agent, for example N,N′-diisopropylcarbodiimide. In both cases the reaction can be performed in an inert solvent which is capable of swelling the resin, such as N,N-dimethylformamide or methylene chloride and at room temperature or under microwave irradiation to minimize the reaction time. Then, the amine IVa is coupled using a tertiary amine as a base. The reaction can be carried out at room temperature or under microwave irradiation.
A carboxylic acid VI, wherein PG represents a protecting group, such as allyl, is reacted with the amine V to obtain the amide VII, using a coupling agent, such as for example the combination of N,N′-diisopropylcarbodiimide and 1-hydroxybenzotriazole. An amine IVb is then added, by means of Michael reaction using a base and a solvent, such as N,N-dimethylformamide or dimethyl sulfoxide to obtain the intermediate VIII after cleavage from the resin using a mixture of trifluoroacetic acid, dichloromethane and water. The intermediate VIII is cyclized (intermediate IX) and deprotected in basic medium yielding the intermediate acid X.
The intermediate X can alternatively be prepared in the solid phase according to scheme 2, wherein the amine V′ can be prepared from the amine IVa either by means of a reductive amination reaction with a glyoxylate in THF-AcOH using a reducing agent such as NaBH3CN, or alternatively by means of alkylation with a bromoacetate or a bromoacetamide using a tertiary amine as a base. Subsequently, it is coupled to the acid VI to obtain the amide VII′. An amine IVb is then added and by means of Michael reaction and subsequent in situ cyclization produces the intermediate ester IX which through basic treatment yields compound X.
A compound of formula Ia can be obtained from the intermediate X by coupling with an amine bound to a solid support Va or Va′, obtained according to the methodology indicated above, in the presence of a coupling agent such as, for example, the combination of HATU and HOBT. The compound of formula Ib can be obtained in the manner similar to the synthesis of compound Ia, except in the case of solid phase in which the starting solid support (IIb) has a halogen group instead of an amino group, such as for example, the chlorotrityl resin, obtaining an acid after cleavage from the resin. The ester Ic can be synthesized by esterification of the corresponding acid Ib by means of common esterification methods in organic synthesis, such as for example, using methanol in an acid medium such as sulfuric acid. In the case of Ib, it can be obtained by means of saponifying the ester Ic. The compounds of formula Id can be obtained by reacting the intermediate X with a primary amine IVc.
An alternative strategy for obtaining the compounds of formula I can be carried out by means of acylating the amine II with an amino acid of formula XI (Method B).
Method B
As is obvious for a person skilled in the field of the invention, it is possible to combine some of the steps of method A with some of the steps of method B to obtain a compound of formula I.
Alternatively, it is possible to obtain the compounds of formula Ie and If as shown in the scheme described below.
The peptide XIII and the pseudopeptide XIV which will be bound to the acid X can be obtained by means of standard peptide synthesis reactions. Therefore, the amine IIa (Z═NH2) or chloride IIb (Z═Cl) resin can be reacted with a suitably protected amino acid (XII), using a suitable coupling agent. Optionally the process can sequentially be repeated, previously deprotecting the amine, to obtain the peptide XIII. The carboxylic acid X then reacts with XIII to obtain the compound Ie.
By combining the amino acid units (XIII) with a glycine unit (following method A or B), the pseudopeptide XIV is obtained, which will lead to obtaining If in the manner similar to that described above.
The primary amines used IVa, IVb and IVc are commercially available or can be obtained by means of known methods (March, Advanced Organic Chemistry, 1991, Ed. John Wiley & Sons) or by using, for example, the schemes described below.
An amine can be obtained by Mitsunobu reaction starting from alcohol and potassium phthalimide in the presence of, for example, diethyl azodicarboxylate (DEAD) and triphenylphosphine in tetrahydrofuran as solvent and the subsequent release with hydrazine hydrate. (Mitsunobu, J. Am. Chem. Soc. 1972, 94, 679-680)
The N-substituted glycines V and XI can be synthesized by means of some of the methods shown below, such as for example, reductive amination of the corresponding glycine with a suitable aldehyde (Scheme 5) using reducing agents such as NaBH4, NaBH3CN or NaBH(AcO)3 or by the nucleophilic substitution of an ester with an amine R—NH2 (Scheme 6).
The following examples serve to better illustrate the invention but they must not be considered as limiting the same.
The nomenclature used in the present document is based on the CFW_CHEMICAL_NAME function in Chemdraw for Excel version 12.
General Data:
The compounds were synthesized using a polystyrene AM RAM resin acquired from Rapp Polymere GmbH (Germany). In the reactions polystyrene syringes with a polyethylene disc were used using an HS501 digital IKA Labortechnik stirrer. In the reactions carried out by microwaves, a CEM Discover model with 10 ml glass reactors was used.
The products were analyzed by:
The high resolution mass spectrometry was carried out by HPLC-HRMS using a Waters Acquity HPLC equipment coupled to a Waters orthogonal acceleration time of flight mass spectrometer model LCT Premier XE. The chromatographic analysis was conducted by means of a Waters Acquity C18 column (10×2.1 mm, 1.7 μm).
Mixtures of CH3CN—H2O with 20 mM formic acid at 0.3 ml/min were used as the mobile phase. The analyses were conducted with a gradient from 50% to 100% of CH3CN in 6 min.
1.8 ml allyl alcohol (26 mmol, 1.3 eq.) were added to a 2 g solution of maleic anhydride (20 mmol) in chloroform. The reaction mixture was stirred at reflux for 5 h. The resulting solution was treated with 1N HCl and was extracted with chloroform. The organic extracts were washed with a saturated sodium chloride solution, dried on anhydrous magnesium sulfate and filtered. The solvent was evaporated at reduced pressure, and the residue obtained was identified as intermediate VI in the form of an oil (95% purity, 85% yield).
A mixture of 2 g of Fmoc-Rink Amide AM polystyrene resin (0.61 mmol/g resin, 1.22 mmol) and 12 ml of 20% piperidine in DMF was stirred in a microwave reactor for 2 min at 35° C. The resin was filtered and washed with DMF (3×15 ml), isopropyl alcohol (3×15 ml) and DCM (3×15 ml). The resin was treated with a solution of bromoacetic acid (III, 840 mg, 5 eq.) and N,N′-diisopropylcarbodiimide (1.15 ml, 5 eq.) in DMF (12 ml). The reaction mixture was stirred for 2 min at 60° C. in a microwave reactor. The resin was filtered and washed with DMF (3×15 ml), isopropyl alcohol (3×15 ml) and DCM (3×15 ml). A solution of 2,4-dichlorophenethylamine (IVa, 1.035 ml, 5 eq.) and triethylamine (0.85 ml, 5 eq.) in 12 ml of DMF was added to the resin and the suspension was stirred for 2 min at 90° C. activated by microwaves. The supernatant was removed and the reaction was repeated in the same conditions. The resin V obtained was filtered and washed with DMF (3×15 ml), isopropyl alcohol (3×15 ml) and DCM (3×15 ml). Then, the resin was treated with a solution of (Z)-2-butenedioic acid allyl ester (VI, 957 mg, 5 eq.), HOBT (825 mg, 5 eq.) and DIC (770 μL, 5 eq.) in DCM:DMF (2:1, 123 ml). The reaction mixture was stirred at room temperature for 30 min and was filtered. The resin was dried and washed with DMF (3×15 ml), isopropyl alcohol (3×15 ml) and DCM (3×15 ml). Then, a solution of 3,3-diphenylpropylamine (IVb, 1.29 g, 5 eq.) and triethylamine (0.85 ml, 5 eq.) in 12 ml of DMF was added to the resin and the suspension was stirred for 3 h at room temperature. The resin was filtered and the reaction was repeated for 16 h at the same temperature. The supernatant was removed and the resin was dried and washed with DMF (3×15 ml), isopropyl alcohol (3×15 ml) and DCM (3×15 ml). Cleavage from the solid phase was performed by treatment with a 60:40:2 TFA/DCM/water mixture (20 ml) for 30 min at room temperature. The reaction mixture was filtered and the solvents were evaporated at reduced pressure. Cyclization was then performed by treating the residue obtained with 20 ml of dioxane for 1.5 h at reflux (monitoring the reaction by HPLC). A 1:2 solution (9 ml) of 4N sodium hydroxide and allyl alcohol was then added and the mixture was stirred for 45 min at reflux. The crude reaction product was acidified with 1N hydrochloric acid and the solvent was evaporated. The resulting solution was extracted with ethyl acetate (3×50 ml) and the organic extracts were washed with a saturated NaCl solution (2×100 ml); they were dried on anhydrous MgSO4 and were evaporated at reduced pressure to obtain 450 mg of the desired product (X, 70% purity, 95% yield at 210 nm). HRMS (M+H)+ calculated for C29H29Cl2N2O4, 539.1504, experimental, 539.1514.
The following compounds were prepared by following a method similar to that described in the example above but by using different amines:
Step 1 Intermediate V′
7.55 mL of Et3N and 2.50 g (27 mmol) of bromoacetamide were added to a solution of 5 g (41 mmol) of 2-(2-pyridyeethylamine in 300 mL of dioxane. The resulting mixture is heated to reflux overnight. The solution is evaporated to dryness and purified in silica gel using a mixture of AcOEt:MeOH:NH3 (10:1:0.01) as eluent, yielding 2.39 g of the intermediate V′. Method B: tr: 0.261, m/z: 180.
Step 2: Intermediate VII′
4.90 mL of Et3N, 3.24 g (24 mmol) of HOBT, 4.60 g (24 mmol) of EDC and the product of step 1 are added to a solution consisting of 2.31 g (16.0 mmol) of maleic acid monoethyl ester in 100 mL of DMF. The suspension formed is kept under stirring at rt for 18 h. It is then treated with water and AcOEt is added, the organic phase is separated and the aqueous phase is extracted one more time with AcOEt. The organic phases are pooled and are successively washed with saturated NaHCO3 solution and brine. It is subsequently dried on anhydrous Na2SO4, the solvent is filtered and evaporated at reduced pressure. 1.5 g of the compound identified as example VII′.13 are obtained. Method B: tr: 1.094, m/z: 306.
Step 3: Intermediate IX
0.8 mL (5.89 mmol) of Et3N and 1.5 g of the intermediate VII′.13 (4.91 mmol) were added to a solution of 2-thiophenylethylamine (0.63 mL, 5.4 mmol) in 40 mL of dioxane and the resulting solution was stirred for 18 h at reflux. The solution was evaporated to dryness and was purified by means of silica gel column chromatography, using a (10:1:0.01) mixture of AcOEt:MeOH:NH3 as eluent, yielding 510 mg of an oil identified as intermediate IX.13 ethyl (2-(3,6-dioxo-4-(2-(pyridin-2-yeethyl)-1-(2-(thiophen-2-yeethyl)piperazin-2-yl)acetate). Method A: tr: 2.289, m/z: 416.
The following intermediates were prepared in the manner similar to intermediate IX.13:
Step 4: intermediate X
1.6 mL of a solution of 1N LiOH were added to a solution of 550 mg (1.32 mmol) of intermediate IX.13 in 15 mL of a MeOH:THF mixture (1:3), and it was left to stir at rt the overnight. It is then diluted in AcOEt and washed with water, the aqueous phase is acidified with a 1N HCl solution until pH=7 and is extracted with AcOEt. Finally, the organic phases are pooled, dried on anhydrous Na2SO4, filtered and the solvent is evaporated at reduced pressure. 330 mg of a colorless oil identified as intermediate X.13 are obtained.
Method B: tr: 1.768, m/z: 388
The following intermediates were prepared in the manner similar to intermediate X.13:
The acid X.1 (100 mg, 1.1 eq.), HOBt (40 mg, 1.5 eq.), HATU (105 mg, 1.5 eq.) and DIPEA (95 μL, 3 eq.) were added to a suspension of resin Va (0.61 mmol/g resin, 0.17 mmol) with the suitable amine and previously swelled with a 2:1 DCM:DMF solution (3 ml). The reaction mixture was stirred at room temperature for 16 h. The resin was dried and washed with DMF (3×3 ml), isopropyl alcohol (3×3 ml) and DCM (3×3 ml) and was subsequently treated with a mixture of 60:40:2 TFA/DCM/water (5 ml) for 30 min at room temperature. The resin was filtered and the filtrate was evaporated at reduced pressure to obtain 73 mg of the desired compound (Ia.1.2, 51% yield, 91% purity). HRMS (M+H)+ calculated for C39H39Cl4N4O4, 767.1725, experimental, 767.1741.
The acid X.2 (100 mg, 1 eq.) was added to a solution of 2-(4-fluorobenzylamino)acetamide (IVc, 28 μL, 1 eq.), DIC (85 μL, 3 eq.) and triethylamine (80 μL, 3 eq.) in 2 ml of DCM and the reaction mixture was stirred at room temperature for 3 h. The crude reaction product was neutralized with NaOH and was extracted with DCM. The organic extracts were washed with saturated sodium chloride, they were dried on anhydrous MgSO4 and were evaporated at reduced pressure to obtain 96 mg of the desired compound
Ia.2.1.
Method A: tr:13.239, m/z: 681
The following intermediates were prepared in the manner similar to compound 1a.2.1:
A solution of bromoacetic acid (275 mg, 5 eq.) and DIPEA (345 μl, 5 eq.) in DMF (3 ml) was added to 200 mg of 2-chlorotrityl chloride resin (1.6 mmol/g Cl/g resin, 0.17 mmol) and the suspension was stirred at room temperature for 1 h. The resin was filtered and washed with DMF (3×3 ml), isopropyl alcohol (3×3 ml) and DCM (3×3 ml). The resin was then treated with methanol (3 ml) for 10 min to remove the unreacted Cl atoms. The supernatant was removed and the residue was washed with DCM (3×3 ml), isopropyl alcohol (3×3 ml) and DMF (3×3 ml). A solution of 2,4-dichlorophenethylamine (IVa, 340 5 eq.) and triethylamine (280 μL, 5 eq.) in 3 ml of DMF was then added to the resin and the suspension was stirred at room temperature for 3 h. After filtering and washing with DMF (3×3 ml), isopropyl alcohol (3×3 ml) and DCM (3×3 ml), acid X (100 mg, 1.1 eq.) was added to the resin in the presence of HOBT (40 mg, 1.5 eq.), HATU (105 mg, 1.5 eq.) and DIPEA (95 μL, 3 eq.) in 2:1 DCM:DMF (3 ml). The reaction mixture was stirred at room temperature for 16 h and was filtered. The resin was dried and washed with DMF (3×3 ml), isopropyl alcohol (3×3 ml) and DCM (3×3 ml). Finally, the resin was treated with a mixture of 5:95 TFA:DCM (5 ml) for 30 min at room temperature, obtaining a crude reaction product which was filtered. The solvent of the filtrate was removed at reduced pressure to obtain 60 mg of the desired compound (Ib.1.2, 42% yield, 91% purity). HRMS (M+H)+ calculated for C39H38Cl4N3O5, 768.1576, experimental, 768.1573.
A mixture of acid Ib.1.2 (30 mg, 1 eq.), methanol (7.5 ml) and H2SO4 (20 μl, 1 eq.) was reacted for 15 h at room temperature. The crude reaction product was neutralized with NaOH and was extracted with DCM. The organic extracts were washed with saturated sodium chloride, dried on anhydrous MgSO4 and evaporated at reduced pressure to obtain 22 mg of the desired compound Ic.1.2 (72% yield, 86% purity). HRMS (M+H)+ calculated for C40H39Cl4N3O5, 782.1722, experimental, 782.1216.
Acid X.1 (100 mg, 1 eq.) was added to a solution of 2,4-dichlorophenethylamine (IVc, 28 μL, 1 eq.), DIC (85 μL, 3 eq.) and triethylamine (80 μL, 3 eq.) in 2 ml of DCM and the reaction mixture was stirred at room temperature for 3 h. The crude reaction product was neutralized with NaOH and was extracted with DCM. The organic extracts were washed with saturated sodium chloride, dried on anhydrous MgSO4 and evaporated at reduced pressure to obtain 96 mg of the desired compound Id.1.2 (73% yield, 89% purity). HRMS (M+H)+ calculated for C37H36Cl4N3O3, 710.1511, experimental, 710.1522.
Rink amide-Fmoc resin (II, 500 mg, 0.305 mmol) was deprotected with 5 ml of 20% piperidine in DMF stirring in a microwave reactor for 2 min at 60° C. The resin was filtered and washed with DMF (3×15 ml), isopropyl alcohol (3×15 ml) and DCM (3×15 ml). The Fmoc-L-Lys(Boc)-OH amino acid (XI, 286 mg, 2 eq.) was then bound to the resin using HOBT (82 mg, 2 eq.) and DIC (96 μL, 2 eq.) in 5 ml of DMF. The mixture was stirred at room temperature for 1 h. The resin was filtered and washed with DMF (3×15 ml), isopropyl alcohol (3×15 ml) and DCM (3×15 ml). Once the Fmoc group was removed with 5 ml of 20% piperidine in DMF for 20 min, the resin was filtered and washed with DMF (3×15 ml), isopropyl alcohol (3×15 ml) and DCM (3×15 ml). Subsequently the resin was treated with a solution of acid X (181 mg, 1.1 eq.), HATU (348 mg, 3 eq.), HOBT (123 mg, 3 eq.) and DIPEA (0.313 ml, 6 eq.) in 5 ml of DMF. The reaction mixture was stirred at room temperature for 16 h. The resin was dried and washed with DMF (3×3 ml), isopropyl alcohol (3×3 ml) and DCM (3×3 ml) and was subsequently treated with a mixture of 80:20:2.5:2.5 TFA/DCM/water/triisopropylsilane (5 ml) for 30 min at room temperature. The resin was filtered and the filtrate was evaporated at reduced pressure. The residue obtained is purified by normal phase chromatography using a gradient of a dichloromethane-methanol-ammonia mixture to obtain 15 mg of the desired compound (Ie.1, 8% yield, 100% purity). MS (M+H)+ calculated for C35H41Cl2N5O4, 666.26, experimental, 666.40.
Rink amide-Fmoc resin (II, 800 mg, 0.42 mmol) was deprotected with 8 ml of 20% piperidine in DMF stirring in a microwave reactor for 2 min at 60° C. The resin was filtered and washed with DMF (3×15 ml), isopropyl alcohol (3×15 ml) and DCM (3×15 ml). The Fmoc-L-Lys(Boc)-OH amino acid (XII, 497 mg, 2 eq.) was the bound to the resin using HOBT (143 mg, 2 eq.) and DIC (165 μL, 2 eq.) in 8 ml of DMF. The mixture was stirred at room temperature for 1 h. The resin was filtered and washed with DMF (3×15 ml), isopropyl alcohol (3×15 ml) and DCM (3×15 ml). Once the Fmoc group was removed with 8 ml of 20% piperidine in DMF for 20 min, the resin was filtered and washed with DMF (3×15 ml), isopropyl alcohol (3×15 ml) and DCM (3×15 ml). The resin was treated with a solution of bromoacetic acid (III, 295 mg, 4 eq.) and DIC (0.33 ml, 4 eq.) in 1:2 DMF:DCM (8 ml) and the mixture was stirred for 20 min at room temperature. The resin was filtered and washed with DMF (3×15 ml), isopropyl alcohol (3×15 ml) and DCM (3×15 ml). A solution of 2,4-dichlorophenethylamine (IVd, 0.32 ml, 4 eq.) and triethylamine (0.295 ml, 4 eq.) in 12 ml of DMF was added to the resin and the suspension was stirred for 3 h at room temperature. The supernatant was removed and the reaction was repeated in the same conditions. The resin was filtered and washed with DMF (3×15 ml), isopropyl alcohol (3×15 ml) and DCM (3×15 ml) to obtain the resin XIV, which was treated with a solution of acid X (274 mg, 2 eq.), HATU (116 mg, 1.6 eq.), HOBT and DIPEA (0.295 ml, 3.2 eq.) in 8 ml of DMF. The reaction mixture was stirred at room temperature for 3 h. The resin was dried and washed with DMF (3×3 ml), isopropyl alcohol (3×3 ml) and DCM (3×3 ml) and was subsequently treated with a mixture of 80:20:2.5:2.5 TFA/DCM/water/triisopropylsilane (5 ml) for 30 min at room temperature. The resin was filtered and the filtrate was evaporated at reduced pressure. The residue obtained was purified by semi-preparative RP-HPLC using a gradient of an acetonitrile-water mixture to obtain 128 mg of the desired compound (If.1.2, 34% yield, 99% purity). HRMS (M+H)+ calculated for C45H50Cl4N6O5, 895.2675; experimental, 895.2648.
Recombinant Apaf-1 produced in insect cells (rApaf-1) was incubated in the presence (at a concentration of 10 μM) or absence (as control) of the compounds to be evaluated in the assay buffer (20 mM Hepes-KOH pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.1 mM PMSF) for 15 minutes at 30° C. The final rApaf-1 concentration was 40 nM. dATP/Mg (Sigma) and purified horse cytochrome c (Sigma) were then added achieving final concentrations of 100 μM and 0.1 μM, respectively. It was incubated for 60 minutes at 30° C. and recombinant procaspase-9 produced in E. coli (rprocaspase-9, final concentration 0.1 μM) was then added and it was incubated for 10 minutes at 30° C. before adding the caspase-9 fluorogenic substrate Ac-LEDH-afc (final concentration 50 μM). The total assay volume was 200 μL. The caspase activity was continuously monitored by means of the afc release at 37° C. in a Wallac 1420 Workstation (λexc=390 nm, λem=510 nm).
The activity values of some compounds described in the examples are indicated in the following table expressed as the percentage of Apaf-1 inhibition.
| Number | Date | Country | Kind |
|---|---|---|---|
| 200901757 | Jul 2009 | ES | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/ES2010/000349 | 7/29/2010 | WO | 00 | 1/26/2012 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2011/012746 | 2/3/2011 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 3560503 | Anand et al. | Feb 1971 | A |
| 5281585 | Duggan et al. | Jan 1994 | A |
| Number | Date | Country |
|---|---|---|
| 0493813 | Jul 1992 | EP |
| 0538882 | Apr 1993 | EP |
| 1698703 | Sep 2006 | EP |
| 1284582 | Aug 1972 | GB |
| 4234375 | Aug 1992 | JP |
| 5117246 | Aug 1992 | JP |
| 2006502418 | Jan 2006 | JP |
| WO9600391 | Jan 1996 | WO |
| 2004030522 | Apr 2004 | WO |
| 2005052177 | Sep 2005 | WO |
| 2007060524 | May 2007 | WO |
| 2008009758 | Jan 2008 | WO |
| Entry |
|---|
| Bali, S., et al. “Corneal Graft Rejection: A Review of Literature and Recent Advances.” WebmedCentral.com. (2010), pp. 1-9. |
| Patani, G.A., et al. “Bioisosterism: A Rational Approach in Drug Design.” Chem. Rev. (1996), vol. 96, pp. 3147-3176. |
| Mayo Clinic. “Alzheimer's treatments: What's on the horizon?” © Mar. 2013. |
| Mitsos, C. “Isosteres in Medicinal Chemistry.” © 2006, pp. 1-7. |
| G Malet, et al.; “Small molecule inhibitors of Apaf-1-related caspase-3/-9 activation that control mitochrondrial-dependent apoptosis,” Cell Death and Differentiation, 2006, pp. 1523-1532, vol. 13. |
| Base De Datos Registry (CAS) EN STN, Recuperado on Line el Dia Nov. 5, 2010, Feb. 17, 2008, RN 1003895-61-1; RN 1003895-57-5; RN 1003895-55-3; RN 1003895-53-1. |
| Göktalay, Gökhan, et al.; “Glycyl-glutamine inhibits nicotine conditioned place preference and withdrawal,” European Journal of Pharmacology, 2006, pp. 95-102, vol. 530. |
| Saxena, Ranjna, et al.; “Studies in Potential Filaricides. 5. 3-Ethyl-8-methyl-1,3,8-triazabicyclo[4.4.0]decan-2-one, a New Antifilarial Agent,” Journal of Medicinal Chemistry, 1971, pp. 929-930, vol. 14. |
| Supplemental European Search Report, Jan. 21, 2013. |
| Number | Date | Country | |
|---|---|---|---|
| 20120122868 A1 | May 2012 | US |
